Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.51 |
| ▸ | CA2 | P00918 | 11/20 | 0.51 |
| ▸ | CA9 | Q16790 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5893648 | 0.82 | CA12 (0.69) | CA1CA2CA9CA12CASP3 | |
| SCHEMBL5434036 | 0.79 | CA1 (0.53) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5434032 | 0.79 | CA1 (0.53) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5739473 | 0.79 | CA1 (0.62) | CA1CA2CA9CA12CA4 | |
| SCHEMBL20436333 | 0.79 | CA1 (0.62) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5741674 | 0.77 | CASP3 (0.62) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL9094147 | 0.76 | ACVR1 (0.61) | CA1CA2CA9CA12CASP3 | |
| SCHEMBL23647047 | 0.76 | CA1 (0.62) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5740077 | 0.76 | TGM2 (0.61) | CA1CA2CA9CA12CA4 | |
| SCHEMBL21999924 | 0.76 | CA1 (0.62) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CA1 2666/4885CA2 1116/4885CA9 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.